Trial Profile
A Phase 1, First-in-human, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Pharmacokinetic Study of ABY 039 in Healthy Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 19 Jun 2020
Price :
$35
*
At a glance
- Drugs Tifalibep (Primary) ; Tifalibep (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors Affibody
- 16 Jun 2020 Status changed from completed to discontinued.
- 15 Jun 2020 According to an Affibody media release, ABY-039 program is terminated due to tolerability observations that would limit the target product profile of subcutaneous high dose once monthly maintentance injections.The termination will become effective June 18, 2020.
- 15 Jun 2020 Status changed from recruiting to completed.